Results 241 to 250 of about 390,053 (266)

Should the age range of the Dutch hrHPV‐based cervical cancer screening program be broadened? A modelling study using cohort effects

International Journal of Cancer, EarlyView.
What's New? Cervical cancer incidence in the Netherlands is increasing among women in younger birth cohorts. This raises concerns about the start and end ages of the country's human papillomavirus (HPV) screening program, which currently includes women ages 30 to 60.
Sylvia Kaljouw, Erik E. L. Jansen, Veerle J. C. Schevenhoven, Inge M. C. M. de Kok   +3 more
wiley   +1 more source

Medical report of the Gynecological department of the faculty obstetric-gynecological clinic

, 1898
В. В. Владимиров
openalex   +2 more sources

Time to pathologic diagnosis of suspicious breast lesions: An institution‐based study in five Ethiopian hospitals

International Journal of Cancer, EarlyView.
What's New? The World Health Organization's Global Breast Cancer Initiative set the benchmark to diagnose breast cancer within 2 months of the first contact with a health care provider. This study analyzed the diagnostic journey of women with breast symptoms at five Ethiopian hospitals. Of the 345 women interviewed who received a diagnostic workup of a
Friedemann Rabe, Sefonias Getachew, Clara Yolanda Stroetmann, Nikolaus Christian Simon Mezger, Tewodros Yalew Gebremariam, Bereket Berhane, Alex Mremi, Blandina Theophil Mmbaga, Pauline Boucheron, Valerie McCormack, Pablo Santos, Adamu Addissie, Eva Johanna Kantelhardt   +12 more
wiley   +1 more source

Diagnostic tasks for obstetrics and gynecology

, 1895
N. Kakushkin
openalex   +2 more sources

Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma

International Journal of Cancer, EarlyView.
What's New? The Tumor‐First workflow is a genetic testing strategy developed to detect pathogenic variants in ovarian cancer risk genes. Recently implemented in the Netherlands, this workflow aims to stratify germline testing while providing information on the effectiveness of PARP inhibitor therapy.
Vera M. Witjes, Joanne A. de Hullu, Dorien M. A. Hermkens, Yvonne H. C. M. Smolders, Julie E. M. Swillens, Sarah‐Lotte Slob, Tjalling Bosse, Marian J. E. Mourits, Margreet G. E. M. Ausems, Tumor‐First Implementation Group, Marjolijn J. L. Ligtenberg, Nicoline Hoogerbrugge, Saskia A.G.M. Cillessen, Johan J.P. Gille, Fenne L. Komdeur, Constantijne H. Mom, Malou L.H. Snijders, J. Margriet Collée, Hendrikus J. Dubbink, Floris H. Groenendijk, Esther Korpershoek, Eva Maria Roes, Christi J. van Asperen, Katja N. Gaarenstroom, Rob B. van der Luijt, Nienke van der Stoep, Elisabeth M.P. Steeghs, Marinus J. Blok, Loes F.S. Kooreman, Edward M. Leter, Brigitte F.M. Slangen, Ernst Jan M. Speel, Hester van Boven, Willemien J. van Driel, Frans B.L. Hogervorst, Lizet E. van der Kolk, Efraim H. Rosenberg, Joost Bart, Lieke P.V. Berger, Arja ter Elst, Annemarie H. van der Hout, Refika Yigit, Anne M.L. Jansen, Wouter Koole, Johanna Krol‐Veraar, Wendy W.J. de Leng, Ronald P. Zweemer, Marjolijn J.L. Ligtenberg, Arjen R. Mensenkamp, Janneke H.M. Schuurs‐Hoeijmakers, Michiel Simons   +50 more
wiley   +1 more source

Loyal Davis, surgery of the liver and transplantation of the kidney. [PDF]

, 1983
Starzl, TE
core  

The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer

International Journal of Cancer, EarlyView.
What's New? Women who are at high risk of breast cancer (BC), either because of a BRCA1/2 mutation or family history, require more aggressive screening. Here, the authors report on the clinical characteristics of the high‐risk women who developed BC during the TESTBREAST study. Of the 1108 participants, 124 (16.5%) developed breast cancer. Their median
Layla Andour, Sophie C. Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M. A. Berends van der Meer, Elma Meershoek‐Klein Kranenbarg, Katja N. Gaarenstroom, Christi J. van Asperen, Rob A. E. M. Tollenaar, Wilma E. Mesker, on behalf of the TESTBREAST study team, J. Aalberts, T. M. A. Berends‐van der Meer, S. C. Hagenaars, L. Andour, W.E. Mesker, R. A. E. M Tollenaar, W. M. Meershoek‐Klein Kranenbarg, K. N. Gaarenstroom, C. M. R. Haekens, K. B. M. I. Keymeulen, J. Remmelzwaal, M. Piek‐den Hartog, E. J. T. Rutgers, C. Drukker, C. Lemstra, A. Prozee, J. de Vries, A. Stam, C. Bandel, I. Meijer, A. E. Dassen, S. Makineli, E. E. van Oers‐Hazelzet, A. J. Witkamp, K. E. Schenk, W. van der Eijk, M. B. E. Menke‐Pluijmers, J. de Droog‐Laane, B. A. Kortmann   +40 more
wiley   +1 more source

Histologically verified penile lichen sclerosus—Incidence in Denmark over 26 years and long‐term risk of penile and non‐penile cancer

International Journal of Cancer, EarlyView.
What's New? About half of penile squamous cell carcinomas are causally associated with inflammatory conditions such as lichen sclerosus (LSc), but few large‐scale studies have assessed the risk of penile cancer in men with LSc. Here, the authors conducted a large nationwide study in Denmark to estimate the risk of penile and non‐penile cancer in men ...
Marianne Gardar Stærk, Emma L. Kaderly Rasmussen, Charlotte Gerd Hannibal, Rasmus Hertzum‐Larsen, Louise Baandrup, Susanne K. Kjær   +5 more
wiley   +1 more source

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

International Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert, Sebastian Lettmaier, Marianne Pavel, Henriette Golcher, Sarina K. Mueller, Florian Fuchs, Carla E. Schulmeyer, Matthias W. Beckmann, Bernd Wullich, Abbas Agaimy, Andre Reis, Arndt Hartmann, Norbert Meidenbauer, Silvia Spoerl, Florian Haller, Evgeny A. Moskalev   +26 more
wiley   +1 more source

Meeting of obstetric and gynecological societies. Protocol No. V

, 1898
Editorial Board
openalex   +1 more source